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Mouse modelPrimary Hyperoxaluria Type 3 is a recently discovered form of this autosomal recessive disease that results
from mutations in the gene coding for 4-hydroxy-2-oxoglutarate aldolase (HOGA1). This enzyme is one of
the 2 unique enzymes in the hydroxyproline catabolism pathway. Affected individuals have increased urinary
excretions of oxalate, 4-hydroxy-L-glutamate (4-OH-Glu), 4-hydroxy-2-oxoglutarate (HOG), and 2,4-
dihydroxyglutarate (DHG). While 4-OH-Glu and HOG are precursor substrates of HOGA1 and increases in their
concentrations are expected, howDHG is formed and howHOG to oxalate are unclear. To resolve these important
questions and to provide insight into possible therapeutic avenues for treating this disease, an animal model of
the disease would be invaluable. We have developed a mouse model of this disease which has null mutations
in the Hoga1 gene and have characterized its phenotype. It shares many characteristics of the human disease,
particularly when challenged by the inclusion of hydroxyproline in the diet. An increased oxalate excretion is
not observed in the KO mice which may be consistent with the recent recognition that only a small fraction of
the individuals with the genotype for HOGA deﬁciency develop PH.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
The PrimaryHyperoxalurias (PHs) are rare genetic disordersmarked
by an increased endogenous oxalate synthesis and a resultant elevation
in urinary oxalate excretion, 3–10 times above normal. These and other
characteristics of the disease have been recently reviewed [1]. This in-
creased oxalate synthesis contributes to kidney stone formation. In ex-
treme cases, tissue deposition of calcium oxalate and kidney failure
may be a result. PH Type 1 (PH1) and PH Type 2 (PH2) have been
well characterized and are known to result from genetic mutations in
enzymes that metabolize glyoxylate. In PH1, alanine–glyoxylate amino-
transferase (AGT) is either not functional or ismistargeted tomitochon-
dria [1]. As a result, a peroxisomal pathway converting glyoxylate to
glycine is absent. In PH2, the enzyme glyoxylate reductase (GR) is deﬁ-
cient, and the conversion of glyoxylate to glycolate in mitochondria and
the cytoplasm is disrupted [2]. PH Type 3 (PH3) is caused by mutations
in the mitochondrial enzyme, 4-hydroxy-2-oxoglutarate aldolase
(HOGA) [3]. This enzyme is involved in trans-4-hydroxy-L-proline
(Hyp) metabolism (Fig. 1), and it catalyzes the cleavage of 4-hydroxy-
2-oxoglutarate (HOG) into pyruvate and glyoxylate. We have proposed
that a buildup of HOG due to HOGA deﬁciency may result in any, University of Alabama atinhibition of GR activity based on results observed in vitro with the pu-
riﬁed enzyme [4,5].
Because Hyp is a major source of the glyoxylate produced in the
body each day, we have argued that it makes a signiﬁcant contribution
to the oxalate produced in individualswith PH1 and PH2 [6]. Hyp is pro-
duced primarily from endogenous collagen turnover, which is estimat-
ed to be 2–3 g/day [7]. As collagen is ~15% Hyp, this turnover results
in the release of 300–450mgof Hyp, whichmust be degraded or excret-
ed as it cannot be used for protein synthesis. Less than 30 mg of Hyp is
excreted in urine each day, predominantly in peptides, with b5 mg of
free Hyp excreted, indicating that most of the Hyp is metabolized [8].
Diet can also be a source of collagen. A single serving of Jello-brand gel-
atin contains a gram of collagen, whichwould contain 150mg of Hyp. A
quarter pound hamburger could contain as much as 6 g of collagen
yielding 780mgof Hyp, if it were rich in ground ‘gristle’ [9]. Thus, signif-
icant levels of Hyp are degraded on a daily basis.
The Hyp catabolic pathway (Fig. 1) involves four enzymatic
reactions [7,10–12]. This metabolism is conﬁned principally to the
liver and kidney [7,13]. The ﬁrst step of the pathway is the ﬂavin-
dependent oxidation of Hyp to 1-pyrroline-3-OH-5-carboxylate (3-
OH-P5C) by Hyp dehydrogenase (HYPDH). This intermediate is con-
verted to 4-hydroxyglutamate (4-OH-Glu) by 1P5C dehydrogenase
(P5CDH), an NAD+-dependent enzyme shared with the proline degra-
dation pathway [11]. Aspartate aminotransferase (AspAT) then utilizes
oxaloacetate to convert 4-OH-Glu to HOG. Importantly, HOG is then
Fig. 1.Hydroxyproline catabolic pathway. The terminal step of the pathway is catalyzedbyHOGA and produces glyoxylate (Glx) and pyruvate (Pyr). Glx can be converted to glycolate (Glc)
and glycine (Gly) bymitochondrial glyoxylate reductase (GR) and peroxisomal alanine-glyoxylate aminotransferase (AGT), respectively.Mutations inHOGA result in PH3 and the buildup
of 4-OH-Glu, HOG and DHG. HOG has been shown to inhibit GR in vitro. The conversion of HOG to DHG by an unknown enzyme is observed onlywith excessive Hyp intake orwith HOGA
deﬁciency. See main text for additional compound and enzyme abbreviation deﬁnitions. The wavy bond on DHG indicates that both the R- and S-isomers have been identiﬁed in urine
samples from PH3 patients.
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glyoxylate can then be converted to glycolate and glycine via GR and
AGT, respectively. In PH patients, the glyoxylate produced from Hyp is
not efﬁciently metabolized and oxalate production is increased via the
activity of lactate dehydrogenase (LDH).
The development of an animalmodel would greatly facilitate further
investigations of Hyp and glyoxylate metabolism in individuals with
PH3. It is not knownwhether theHOG that builds up is themajor source
of the increased oxalate synthesis or whether other pathways are in-
volved. Individuals with PH3 have also been shown to synthesize signif-
icant amounts of 2,4-dihydroxyglutarate (DHG), presumably derived
from the reduction of HOG (Fig. 1) [14]. The pathway that converts
HOG to DHG requires investigation, as it could be exploited therapeuti-
cally to enhance the disposal of HOG to limit its conversion to oxalate.
Through the knockout mouse project (KOMP), we report here the de-
velopment of a mouse model that has a suitable phenotype for such
studies when challenged with Hyp.
2. Materials and methods
2.1. Chemicals
Reagent grade chemicals were obtained from either Sigma–Aldrich
Chemicals (St Louis, MO) or Fisher Scientiﬁc (Pittsburgh, PA). Trans-4-
L-hydroxyproline for feeding studies was purchased from Sigma–Al-
drich. The synthesis of 13C5-Hyp has been previously described [13].
DL-4-Hydroxy-2-ketoglutaric acid lithium salt (HOG) was purchased
from Sigma–Aldrich. Fluorescein-isothiocyanate-labeled sinistrin
(FITC-S) was purchased from Fresenius Kabi Austria GmbH, Graz,
Austria.
2.2. Animals
The mouse strain used for this research project was created
from embryonic stem cell clone (EPD0380_4_H08) obtained from the
NCRR-NIH supportedKOMPRepository (www.komp.org) and generated
by the CSD consortium. Methods used on the CSD targeted alleles
have been published [15]. Hoga1 heterozygous mice were intercrossed
to generate Hoga1 knock out (KO) and wild type (Wt) mice, and these
animals were used to obtain phenotypic data. Mice were genotyped
by tail snip DNA, using a polymerase chain reaction (PCR) with primers
HOGA1 Forward (binds to 5′ homology arm), 5′-CCCGGGCAGCTGCTCT
GCTCCT, HOGA1 Reverse (binds to the 3′ homology arm), 5′-GCCCCG
AAACCGCCCAGCAA, and 5′ Universal (LAR3)-reverse, 5′- CACAACGG
GTTCTTCTGTTAGTCC -3′. Agarose electrophoresis of PCR products
yielded a 597 bp product for the wild type allele (primers HOGA1F&R)
and a 383 bp product for the knock out allele (primers HOGA1&LAR3).
Mice were maintained in a barrier facility with a 12 h light/dark
cycle and an ambient temperature of 23 ± 1°C and had free accessto food and water. All animal studies were approved by the Institutional
Animal Use and Care Committee of the University of Alabama at
Birmingham.
2.3. Metabolic cage collections
Animals (n = 5–6 per sex/per strain), 12–14 weeks of age, were
equilibrated in Nalgene metabolic cages (Nalgene, Rochester, US) for
1 week and had free access to water and a custom calcium deﬁcient,
high sucrose basal diet (TD.130032) designed by Harlan Laboratories
(Madison, WI), to which calcium chloride was added at 5 mg per
gram dry diet. The custom, puriﬁed diet contained a very low back-
ground oxalate content (12.9 ± 1.1 μg oxalate per gram diet) and is de-
void of Hyp. By weight, the diet contains 19.6% protein (whey protein
isolate), 57.7% carbohydrate (maltodextrin and sucrose), 6.6% fat (lard
and corn oil), and 10.3% cellulose. For Hyp feeding, the custom diet
was supplemented with 1% Hyp. After equilibration for 1 week on the
diet, 24 h urines were collected on 1-mlmineral oil to prevent evapora-
tion and 50 μl of 2% sodium azide to prevent bacterial growth. The sta-
bility of HOG in urine samples collected this way and stored at−80°C
was conﬁrmed. Three to four 24 h urines were performed for each
mouse. Urine collections with creatinine values 25% lower/higher than
mean values for each animal were considered incomplete/over collec-
tions and were discarded.
2.4. 13C5-
15N-Hyp intravenous infusion
Male Wt and KO mice (n = 4) under isoﬂurane anesthesia were
catheterized via the jugular vein with a funnel catheter (Instech Lab
Inc., PA), which was attached to a swivel (Instech Lab Inc., PA)
and mounted to the metabolic cage. 13C5-15N-Hyp was prepared in
0.9% saline containing FITC-S (0.5 mg/ml) and infused at a rate of
10 μmoles/h/kg. FITC-S was included to ensure consistency of urine
collections and infusion rates between animals. After a three day re-
covery period, three consistent 24 h urines were collected from each
animal. The 24 h urines containing less than 75% of FITC-S infused
were not included in the data analysis.
2.5. Glomerular ﬁltration rate
Aminiaturized Non-Invasive-Clearance (NIC) technique to measure
kidney function in consciousmicewas applied to determineGFR, as pre-
viously described [16,17]. The NIC-Kidney device (Mannhein Pharma
and Diagnostics, Mannheim, Germany) allows for transcutaneous mea-
surement of the elimination kinetics of the ﬂuorescent renal marker
FITC-Swithout surgery or blood and urine collection. Brieﬂy, theNIC de-
vice was attached to the back of mice using a double-sided adhesive
patch under anesthesia with 2% isoﬂurane. After a 5-min baseline
recording, FITC-S (10–30 mg/100 g body weight) was dissolved in
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Mice were allowed to recover from anesthesia and data were acquired
for 90–120 min. The half-time of FITC-S elimination was determined
using the established one compartment model and GFR was calculated.
2.6. Sample preparation
For oxalate determination, part of the urine collection was acidiﬁed
to pH b1 with hydrochloric acid prior to storage at−80°C to prevent
any possible oxalate crystallization that can occur with cold storage
and/or oxalogenesis associated with alkanization. The remaining non-
acidiﬁed urine was frozen at−80°C for the measurement of other uri-
nary parameters. Plasma preparations were ﬁltered through Nano-sep
centrifugal ﬁlters (VWR International, Batavia, IL) with a 10,000 nomi-
nal molecular weight limit (NMWL) prior to ion chromatography anal-
ysis. Centrifugal ﬁlters were washed with 0.1 M HCl prior to sample
ﬁltration to remove any contaminating trace organic acids trapped in
the ﬁlter device. Liver tissue was freeze clamped in liquid nitrogen im-
mediately after sacriﬁce and stored at−80°C. Liver tissue (10%)was ho-
mogenized in hypotonic lysis buffer containing 25 mM HEPES, pH 7.1,
and 0.1% Triton X-100 and extracted with 10% trichloroacetic acid
(TCA),with subsequent removal of the TCA aspreviously described [18].
2.7. HOGA expression
Western blot analysis was performed as previously described [5].
HOGA enzymatic activity was assessed by measuring the production
of glyoxylate from the cleavage of HOG in a crudemitochondrial prepa-
ration isolated as previously described [19]. 100 μL reactions contained
1% mitochondrial homogenate, 100 mM TRIS pH 8.5, and 0.5 mM
HOG. The reactionswere run at 37°C in triplicate for 15min, and the re-
action stopped with the addition of 11 μL 5 M perchloric acid (PCA).
Glyoxylate was measured in PCA extracts by reversed phase HPLC
after derivatization with phenylhydrazine, as previously described [18].
2.8. Analytical methods
Urinary creatininewasmeasured in non-acidiﬁed urines on a chem-
ical analyzer and oxalate in acidiﬁed urine by ion chromatography (IC),
as previously described [20]. IC coupled with negative electrospray
mass spectrometry (IC/MS) (Thermo Fisher Scientiﬁc Inc., Waltham,
MA) was used to measure glycolate, HOG and DHG. For glycolate mea-
surement, the IC equipment consisted of a Dionex™ ICS-5000 system
with an AS15, 2 × 150 mm, anion exchange column at a controlled
temperature of 30°C and a Dionex™ ERS™ 500 anion electrolytically-Table 1
24 h urine, plasma, and glomerular ﬁltration rate measurements fromWt and Hoga1 KO mice
Wt
Male F
Body weight (g) 28.4 ± 0.1 2
Urine volume (ml) 2.1 ± 0.5
Urinary creatinine (mg) 0.46 ± 0.02 0
Urinary oxalate (μg/mg Cr) 74.3 ± 5.6 6
Urinary glycolate (μg/mg Cr) 103 ± 4
Urinary HOG (μg/mg Cr) 8.8 ± 2.0
Urinary DHG (μg/mg Cr) 13.8 ± 1.2 1
Plasma DHG (μM) 0.11 ± 0.02 0
Plasma glycolate (μM) 32.4 ± 6.6
GFR (μl/min) 203 ± 8
FE-Glc (%) 9.3 ± 1.3
Data are expressed as means ± SD. Student t-test was used to determine signiﬁcant differenc
mined. HOG was not detected in the plasma of any animals (b0.2 μM).
a Signiﬁcant differences between sexes within each strain.
b Signiﬁcant differences between Wt and Hoga1 KO mice.regenerated suppressor. A gradient of KOH from 3 to 80 mM over
30 min at a ﬂow rate of 0.3 ml min−1 was used to separate sample an-
ions. The mass spectrometer (MSQ-PLUS) was operated as previously
described [21]. Samples were diluted in the same amount of 13C2-
glycolate and selected-ion monitoring (SIM) was performed at the
followingmass/charge ratios, 12C2-glycolate (SIM75) and 13C2-glycolate
(SIM77). For HOG and DHG quantiﬁcation, an AS11-HC-4 μm,
2 × 150 mm, anion exchange column was used. A gradient of KOH
from 0.5 to 80 mM over 60 min at a ﬂow rate of 0.38 ml min−1 was
used to separate anions in samples. The MSQ-PLUS mass detector was
operated in ESI negative mode, needle voltage 1.5 V, cone voltage
30 V, and a temperature of 500°C. The column eluent was mixed with
50% acetonitrile at 0.38 ml min−1 using a zero dead volume mixing
tee prior to entry into the mass spectrometer. Selected-ion monitoring
(SIM) was used to measure the isoptomers of HOG and DHG at the fol-
lowing mass/charge ratios; HOG (SIM161), 13C5-HOG (SIM166), DHG
(SIM163) and 13C5-DHG (SIM168). Commercial standards for DHG do
not exist, so its levels were estimated using pure standards of 2-
hydroxyglutaric acid. Plasma Hyp was measured as previously de-
scribed [6]. The mole percent enrichment of 13C5-15N -Hyp in plasma
wasmeasured by gas chromatography-mass spectroscopy byMetabolic
Solutions (Nashua, NH). The contribution of Hypmetabolism to urinary
oxalate excretion was calculated as previously reported for glycine [22].
A Coomassie Plus protein assay kit (Pierce, Rockford, IL), with bovine
serum albumin (BSA) as the standard, was used to determine protein
concentrations in tissue preparations.
2.9. Statistical analysis
Themean of at least two 24h urine analyte determinationswas used
to characterize excretions in each mouse. Student's t-test was used to
compare sex differences and impact of Hyp feeding or 13C5-15N-Hyp in-
travenous infusion. Data are expressed as mean ± SD. The criterion for
statistical signiﬁcance was P b 0.05.
3. Results
3.1. Growth, development, and HOGA expression
Hoga1 KO mice developed similarly to Wt mice with regards to
weight gain, urine volume and creatinine output (Table 1). Western
blot analysis showed HOGA present in liver mitochondria from Wt
animals, but not KOmice (Fig. 2A). Mitochondria fromWt animals pos-
sessed HOGA enzymatic activity, but not mitochondria from Hoga1 KO
mice (Fig. 2B).fed a puriﬁed diet devoid of Hyp.
Hoga1 KO
emale Male Female
3.4 ± 1.6a 29.6 ± 2.3 24.8 ± 1.3a
2.5 ± 0.7 2.8 ± 0.3b 2.5 ± 0.7
.44 ± 0.05 0.49 ± 0.05 0.43 ± 0.06
6.1 ± 4.6a 79.1 ± 10.6 73.1 ± 6.9
436 ± 71a 111 ± 11 439 ± 74a
8.8 ± 1.8 9.4 ± 1.2 7.6 ± 1.3
1.0 ± 1.2a 112 ± 23b 76.0 ± 15.5b
.18 ± 0.19 0.33 ± 0.09b 0.39 ± 0.18
37.5 ± 3.7 29.7 ± 1.4 38.0 ± 4.4a
ND 229 ± 26 ND
ND 6.8 ± 1.5 ND
es between sexes and phenotype, and P b 0.05 was considered signiﬁcant. ND. Not deter-
Fig. 2.HOGAprotein and activity levels frommitochondria isolated fromWt andHoga1KOmice. (A)Western blot of analysiswith polyclonal rabbit antibodies against recombinant human
HOGA.Western blot key: 1, human liver; 2, blank; 3, recombinant humanHOGAprotein (32,878Da); 4 and 6,Wtmice; 5 and 7,HogaKOmice. (B) Enzymatic activity expressed asmean±
SD. LOD, 1.9 pmol glyoxylate/min/mg protein.
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Biochemical analyses of plasma and urine from KO andWt mice fed
a Hyp-free diet are shown in Table 1. DHG levels in plasma and urine
were signiﬁcantly higher in Hoga1 KO mice compared to Wt animals.
There were no other signiﬁcant differences between Hoga KO and Wt
animals. Liver HOG and DHGwere below detection limits. Interestingly,
female animals had higher levels of glycolate in plasma and 24 h urine
collections compared to male animals. The fractional clearance of
glycolate (FE-Glc) relative to FITC-S was lower in male Hoga KO mice.
In both sexes signiﬁcant reabsorption of glycolate by the kidney oc-
curred. It is also important to note that the Hoga1 KO mice did not ex-
hibit hyperoxaluria under a Hyp-free diet, a marked contrast to PH3
patients.
3.3. Hydroxyproline feeding
As HOGA is in the pathway for Hyp catabolism (Fig. 1), we investi-
gated how male and female mice metabolized Hyp by supplementing
their diets with 1% Hyp. HOG and DHG levels in urine (Fig. 3), plasma
HOG and DHG (Table 2), and DHG levels in liver tissue (Table 2) were
signiﬁcantly higher in KO animals compared to Wt mice of both sexes.
HOG levels in liver tissue were only higher in female KO mice. Despite
the increase in the production of HOG and DHG, as seen in human
PH3 patients, the KO and Wt mice excreted similar amounts of oxalate
(Fig. 4A). The urinary glycolate levels of Hyp-fed Wt mice of both
sexes, however, showed a marked increase (~10-fold for males, ~14-
fold for females; Fig. 4B, Table 1). In contrast, the urinary glycolate
level of Hyp-fed female Hoga1 KO mice increased to a lesser extent
(~6-fold), and the amount of glycolate in plasma decreased ~2-fold
(Table 2).
3.4. 13C5-
15N-Hyp intravenous infusion
To more precisely determine whether the HOGA deﬁciency altered
the metabolism of Hyp to oxalate, glycolate, HOG and DHG, Wt andFig. 3.24h urinaryHOG(A) andDHG (B) excretionwith 1%Hyp feeding inWt (□) andHoga1KO
each strain. #, signiﬁcant differences between Wt and Hoga1 KO mice.KO male mice were continuously infused with low levels of 13C5-15N-
Hyp (Table 3). The infusion with 13C5-15N-Hyp enriched plasma Hyp
to similar extents in both strains. Urinary 13C2-oxalate and 13C2-
glycolate excretions were also similar in Wt and KO animals. Calcula-
tions indicated that the contribution of Hyp metabolism to urinary oxa-
late excretion was similar inWt and KO animals. Urinary 13C5-HOGwas
not detected in Wt and KO animals. However, 13C5-DHG was detected
in urine of KO animals, but not Wt animals. This indicates that the
DHG detected in Wt animals on a Hyp-free diet (Table 1; ~12 μg/mg
Cr) is not derived from Hyp metabolism.
4. Discussion
Mutations in the gene encoding HOGA were recently identiﬁed as
causes of PH Type 3 [3]. This disease has an average earlier age of
onset and a slower progression than PH1 or PH2 [23]. HOGA is one of
two enzymes unique to the Hyp catabolism pathway (Fig. 1), and splits
HOG into pyruvate and glyoxylate. There are no known sex differences
in urinary excretions in individuals with the disease. Affected individ-
uals have increased excretions of oxalate, 4-OH-Glu, HOG and DHG in
their urine [3,5,24]. The increases in 4-OH-Glu and HOG are expected,
as they represent the substrate and product of aspartate aminotransfer-
ase, the enzyme preceding HOGA in the pathway. How HOG is cleaved
in the absence of HOGA and whether DHG is also broken down and ul-
timately converted to glyoxylate are open questions.
Chiral analysis of the HOG in the urine of PH3 patients is consistent
with the conversion of Hyp to the R-isomer, maintaining the stereo-
chemistry at the 4-position from Hyp (Fig. 1) [14]. The ﬁnding of an el-
evation of two stereoisomers of DHG in that study suggests that more
than one enzyme may be able to reduce HOG to DHG, but the identity
and localization of these enzymes remain to be determined. The avail-
ability of an animal model that provides access to tissue will facilitate
the identiﬁcation of the enzymes involved. It is possible that Hoga1 KO
mice could be useful in the development of speciﬁc therapeutic ap-
proaches that increase the formation of DHG from HOG and limit its
conversion to oxalate.(■)mice. Data are expressed asmean (SD). *, signiﬁcant differences between sexeswithin
Table 2
Liver and plasma measurements in Wt and Hoga1 KO mice after 1% hydroxyproline
feeding.
Wt Hoga1 KO
Male Female Male Female
Plasma HOG (μM) b0.2 0.69 ± 0.44 5.9 ± 5.1 37 ± 9a, b
Plasma DHG (μM) 0.36 ± 0.11 0.52 ± 0.37 7.2 ± 1.6b 8.2 ± 1.9b
Plasma glycolate (μM) 84 ± 2 318 ± 49a 92 ± 6 130 ± 29b
Liver HOG
(nmoles/mg protein)
b0.01 b0.01 b0.01 1.0 ± 0.3a, b
Liver DHG
(nmoles/mg protein)
b0.01 0.1 ± 0.1 0.2 ± 0.0b 1.3 ± 0.4a, b
Data are expressed asmeans±SD. Student t-testwas used to determine signiﬁcant differ-
ences between sexes and phenotype, and P b 0.05 was considered signiﬁcant.
a Signiﬁcant differences between sexes within each strain.
b Signiﬁcant differences between Wt and Hoga1 KO mice.
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(KOMP), that contained a deletion in their Hoga1 gene. These mice
lacked Hoga1 gene expression and protein production (Fig. 2). When
placed on a Hyp-free diet, the phenotype of these mice was signiﬁcant
only in the excretion of larger amounts of DHG (males 8-fold higher
than Wt animals and females 7-fold higher) (Table 1). These observa-
tions support endogenous Hyp breakdownmaking a substantial contri-
bution to urinary oxalate and glycolate levels. DHG levels increased
furtherwith Hyp feeding (Fig. 3B, Table 2), and our experiments suggest
that DHG may be the main end product of HOG metabolism in the
Hoga1 KO mouse. Surprisingly, oxalate excretion was not elevated
even with Hyp feeding (Fig. 4). This phenomenon may in part be due
to the presence of AGT in mouse liver mitochondria as weIl as in perox-
isomes, asAGT is only present in the peroxisomes in humans.Mitochon-
drial AGT activity provides the mouse with an additional means of
removing glyoxylate other than through GR activity. The combination
of AGT activity and a higher conversion of HOG to DHG in mice com-
pared to humans may limit the availability of glyoxylate for conversion
to oxalate. It is also possible that the mild phenotype in Hoga1 KOmice
matches the bulk of the individuals with the PH3 genotype. The geno-
type for PH3 is the most common amongst the various PH types based
on an analysis of carrier frequencies in the population [23]. As only a
small fraction of these individuals presentwith disease,most commonly
with calciumoxalate kidney stones, the phenotype of themajority of in-
dividuals with the genotype is not known. It will be informative to de-
termine their ability to metabolize Hyp and their urinary excretions of
oxalate, HOG and DHG.
We have previously suggested that the hyperoxaluria observed in
individuals with PH3 is caused by an inhibition of GR activity due to
the increased concentration of HOG, based on in vitro observations [5].
An inhibition of GR activity might be expected to decrease the synthesis
of glycolate from glyoxylate. The formation of 13C2-glycolate from
13C5-15N-Hyp, however, was comparable in male Wt and Hoga KO
mice (Table 3). This contrastedwith the lack of 13C2-glycolate formationFig. 4. 24 h urinary oxalate (A) and glycolate (B) excretionwith 1%Hyp feeding inWt (□) andHo
within each strain. #, signiﬁcant differences between Wt and Hoga1 KO mice.in Grhpr KO mice, where the inhibition of glycolate formation and the
role of GR are very clear [13]. The inhibition of GR may have resulted
in the larger contribution ofHypmetabolism to urinary oxalate excretion
in KO mice compared to Wt mice. As discussed above, the presence of
AGT in the mitochondria and peroxisomes of the murine liver is a con-
founding factor. Notably, excess Hyp feeding did result in female Hoga1
KO animals excreting signiﬁcantly less urinary glycolate than female
Wt animals, supporting the idea that only when HOG levels reach high
concentrations within both the mitochondrion and cytosol is GR activity
signiﬁcantly inhibited. The lack of a difference in urinary glycolate excre-
tion between Wt and Hoga1 KO male animals with Hyp feeding may be
due to this sex metabolizing glycolate more efﬁciently than females and
thus blunting any urinary glycolate differences between the strains.
The clearance of glycolate relative to FITC-S indicated that ~90%was
reabsorbed (Table 1). This is greater than the clearance relative to creat-
inine we reported in studies with human subjects which indicated that
~40%was reabsorbed [6]. Howmuch of this reabsorbed glycolate is me-
tabolized will require further experimentation, perhaps comparing the
glycolate concentration in a renal vein with that in the arterial supply.
A possible product of glycolate oxidation in the kidney is glyoxylate,
which could result in further oxalate production. While an enzyme
that could catalyze this conversion has not been identiﬁed, it is possible
that long chain hydroxy-acid oxidase (HAOX2) or an aldehyde oxidase
that has some afﬁnity for glycolate could be involved. Two brothers
who appear to lack functional glycolate oxidase activity with an elevat-
ed urinary glycolate but normal oxalate excretion have recently been
identiﬁed [25]. This ﬁnding warrants investigation due to glycolate oxi-
dase being considered as a target enzyme for lowering endogenous ox-
alate production [26].
The infusion experiments with 13C5-15N-Hyp (Table 3) conﬁrm that
HOG is broken down to 13C2-glycolate and 13C2-oxalate despite the ab-
sence of HOGA activity in the KOmice. These results suggest that anoth-
er enzymewith lyase-like activity is able to split HOG into pyruvate and
glyoxylate when the HOG concentration increases due to the lack of
HOGA activity. Our tissue measurements of HOG and DHG suggest
that the pathway converting HOG to DHG is present in the liver. N-
acetylneuraminate lyase (NAL) was suggested as a candidate enzyme
but we found that the NAL from Escherichia coli had minimal activity
with HOG as a substrate [5]. Enzymes that could potentially recognize
HOG as a substrate for conversion to DHG include 2-oxoglutarate dehy-
drogenase (OGDH), a 2-oxoglutarate dehydrogenase-like enzyme
(OGDHL), or a dehydrogenase E1 transketolase domain containing pro-
tein (DHTK1) [27]. Work in our labs and others are in progress to deter-
mine the alternativemetabolic pathways for HOG and DHG and the ﬂux
of labeled Hyp in normal and PH1-3 patients.
In summary, normal individuals and mice excrete very low levels of
HOG in urine (Table 1) [5,14]. HOG excretion is elevated in subjectswith
PH3 [5,14], but not inHoga1KOmice until they are challengedwith Hyp
feeding. Female Hoga1 KO mice show the greatest response, and could
be the model of choice for monitoring HOG production. Elevated DHG
excretions are observed in both PH3 subjects and Hoga1 KO mice andga1KO(■)mice. Data are expressed asmean (SD). *, signiﬁcant differences between sexes
Table 3
24 h urinary and plasma carbon 13measurements inmaleWt andHoga1 KOmice infused
with 13C5-15N-Hyp infusion.
Wt Hoga KO
Plasma Hyp (μM) 25.5 ± 6.5 22.7 ± 2.6
Plasma 13C5-15N-Hyp mole percent enrichment 34.2 ± 6.0 31.8 ± 5.4
Urinary 13C2-oxalate (μg/mg Cr) 5.5 ± 1.6 6.8 ± 1.3
Urinary 13C2-glycolate (μg/mg Cr) 2.9 ± 0.9 3.5 ± 1.7
Urinary 13C5-DHG (μg/mg Cr) b0.02 8.9 ± 3.5#
Contribution of Hyp metabolism to urinary
oxalate excretion (%)
22.1 ± 2.2 27.3 ± 5.6
2705X. Li et al. / Biochimica et Biophysica Acta 1852 (2015) 2700–2705are substantially increased in Hoga1 KO mice with Hyp feeding. This
pattern of excretions indicates that both sexes of the Hoga1 KO mouse
will be useful models to study both DHG formation and the hydrolysis
of HOG to pyruvate and glyoxylate. Decreasing the breakdown of HOG
and increasing the formation of DHG from HOG are potential therapeu-
tic strategies for decreasing oxalate synthesis in individuals with PH3. In
addition, these studies support the need to develop animal models of
PH3 where AGT is not present in the mitochondrion. These alternative
models have the potential to remove the confounding interpretation
of metabolic data and to more closely recapitulate the PH3 phenotype.
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